Treatment with adalimumab ameliorated the signs and symptoms of disease and improved physical function in patients with active nonpsoriatic peripheral SpA who exhibited an inadequate response or intolerance to NSAIDs , with a safety profile consistent with that observed in patients with AS , PsA , or other immune-mediated diseases .